EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Exon skipping peptide-conjugated morpholinos downregulate dynamin 2 to rescue centronuclear myopathy

Foteini Moschovaki-Filippidou, Juliana de Carvalho Neves, Nadège Diedhiou, Yahya Jad, Johann Böhm iD, Matthew J A Wood, Miguel A Varela, Jocelyn Laporte iD

Brain · 2025

DOI: 10.1093/brain/awaf249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, 2025. Verfasst von Foteini Moschovaki-Filippidou und 7 weiteren Autor:innen. Beteiligte Einrichtung: IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire), Inserm U1258, CNRS UMR7104, Université de Strasbourg, Illkirch 67404, France. Hauptthemen laut MEDLINE: Dynamin II, Myopathies, Structural, Congenital, Morpholinos. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Interdisciplinary Thematic Institute IMCBio, University of Strasbourg, CNRS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Centronuclear myopathies (CNM) are rare congenital disorders characterized by muscle weakness and disorganization of myofibres. These conditions can result from dominant mutations in the DNM2 gene encoding the GTPase dynamin, making them potential targets for antisense therapy. Preclinical studies suggested decreasing DNM2 as a therapy but a recent clinical trial with antisense oligonucleotides did not effectively address the disease and showed some non-muscle toxicity. Here, to promote DNM2 downregulation in muscle versus other tissues, we used an exon skipping peptide-conjugated phosphorodiamidate morpholino (PPMO) targeting Dnm2 exon 6 splicing in the Dnm2R369W/+ mouse model for the moderate CNM form. Intravenous administration of PPMOs at an early age (4 weeks) significantly downregulated intact (i.e. normally spliced) Dnm2 mRNA (∼50%) and DNM2 protein levels in muscle. This intervention led to a rescue of muscle force, thereby preventing disease progression. PPMO administration at a later age (8 weeks), when mice demonstrated established phenotypes, efficiently decreased intact Dnm2 mRNA and protein levels in muscle, resulting in reversal of the disease phenotype and significant improvement in muscle force (from 11 mN/mg to nearly 16 mN/mg). Overall, our results indicate that PPMOs targeting Dnm2 splicing effectively decrease intact Dnm2 mRNA and protein levels in muscle and rescue muscle force in Dnm2R369W/+ mice, suggesting a promising translational approach for patients with DNM2 mutations and potentially other forms of CNM. More generally, it provides the concept of using the exon skipping strategy to decrease the protein expression of a target gene, rather than producing a shorter functional protein as is generally done.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dynamin IIMyopathies, Structural, CongenitalMorpholinosAnimalsMiceDown-RegulationExonsDisease Models, AnimalMuscle, SkeletalPeptides

Stichwörter der Autor:innen

centronuclear myopathycongenital myopathydynamin 2exon skippinggene therapyskeletal muscle

Substanzen

Dynamin IIMorpholinosDNM2 protein, mousePeptides

Autor:innen und Institutionen

  • IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire), Inserm U1258, CNRS UMR7104, Université de Strasbourg, Illkirch 67404, France.
  • Department of Paediatrics, Institute of Developmental and Regenerative Medicine (IDRM), University of Oxford, Oxford OX3 7FZ, UK.
  • MDUK Oxford Neuromuscular Centre, Department of Paediatrics, Oxford OX3 9DU, UK.

ORCID-Profile: Johann Böhm, Jocelyn Laporte

Förderung

  • Interdisciplinary Thematic Institute IMCBio
  • University of Strasbourg
  • CNRS
  • Inserm
  • IdEx Unistra
  • SFRI-STRAT'US project
  • EUR IMCBio
  • French Investments for the Future Program

Zitieren

APA

Moschovaki-Filippidou, F., de Carvalho Neves, J., Diedhiou, N., Jad, Y., Böhm, J., Wood, M. J. A., Varela, M. A., & Laporte, J. (2025). Exon skipping peptide-conjugated morpholinos downregulate dynamin 2 to rescue centronuclear myopathy. Brain. https://doi.org/10.1093/brain/awaf249

Vancouver

Moschovaki-Filippidou F, de Carvalho Neves J, Diedhiou N, Jad Y, Böhm J, Wood MJA, et al. Exon skipping peptide-conjugated morpholinos downregulate dynamin 2 to rescue centronuclear myopathy. Brain. 2025. doi:10.1093/brain/awaf249

BibTeX
@article{MoschovakiFilippidou2025,
  author = {Moschovaki-Filippidou, Foteini and de Carvalho Neves, Juliana and Diedhiou, Nadège and Jad, Yahya and Böhm, Johann and Wood, Matthew J A and Varela, Miguel A and Laporte, Jocelyn},
  title = {Exon skipping peptide-conjugated morpholinos downregulate dynamin 2 to rescue centronuclear myopathy},
  journal = {Brain},
  year = {2025},
  doi = {10.1093/brain/awaf249}
}
Kostenlos starten →